In an effort to advance its Alzheimer’s research, AbbVie has agreed to acquire Aliada Therapeutics for US$1.4 B in cash. The deal provides AbbVie with access to Aliada’s lead compound, ALIA-1758, a Phase I anti-pyroglutamate amyloid beta (3pE-Abeta) bispecific antibody for the treatment of Alzheimer’s disease, as well as its Modular Delivery (MODEL™) platform for enhanced drug delivery across the blood-brain barrier. The acquisition will allow AbbVie to strengthen its position in neurology and help to offset potential revenue losses from the patent expirations of its key assets.